TWI537259B - 吡啶酮衍生物 - Google Patents
吡啶酮衍生物 Download PDFInfo
- Publication number
- TWI537259B TWI537259B TW102103411A TW102103411A TWI537259B TW I537259 B TWI537259 B TW I537259B TW 102103411 A TW102103411 A TW 102103411A TW 102103411 A TW102103411 A TW 102103411A TW I537259 B TWI537259 B TW I537259B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- compound
- substituents
- ray diffraction
- dihydropyridine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012017971 | 2012-01-31 | ||
| US201261746039P | 2012-12-26 | 2012-12-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201335148A TW201335148A (zh) | 2013-09-01 |
| TWI537259B true TWI537259B (zh) | 2016-06-11 |
Family
ID=48905312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102103411A TWI537259B (zh) | 2012-01-31 | 2013-01-30 | 吡啶酮衍生物 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8933103B2 (enExample) |
| EP (1) | EP2810937B1 (enExample) |
| JP (1) | JP6006241B2 (enExample) |
| KR (1) | KR102078530B1 (enExample) |
| CN (1) | CN104185627B (enExample) |
| AU (1) | AU2013216006B2 (enExample) |
| BR (1) | BR112014018702B1 (enExample) |
| CA (1) | CA2863515C (enExample) |
| CO (1) | CO7071126A2 (enExample) |
| CY (1) | CY1118656T1 (enExample) |
| DK (1) | DK2810937T3 (enExample) |
| ES (1) | ES2617484T3 (enExample) |
| HR (1) | HRP20170303T1 (enExample) |
| HU (1) | HUE031624T2 (enExample) |
| IL (1) | IL233863A (enExample) |
| LT (1) | LT2810937T (enExample) |
| MX (1) | MX351812B (enExample) |
| MY (1) | MY165215A (enExample) |
| NZ (1) | NZ627586A (enExample) |
| PH (1) | PH12014501719B1 (enExample) |
| PL (1) | PL2810937T3 (enExample) |
| PT (1) | PT2810937T (enExample) |
| RS (1) | RS55728B1 (enExample) |
| RU (1) | RU2632885C2 (enExample) |
| SG (1) | SG11201404505PA (enExample) |
| SI (1) | SI2810937T1 (enExample) |
| SM (2) | SMT201700065T1 (enExample) |
| TW (1) | TWI537259B (enExample) |
| WO (1) | WO2013115280A1 (enExample) |
| ZA (1) | ZA201405486B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013162061A1 (ja) * | 2012-04-26 | 2013-10-31 | 第一三共株式会社 | 二環性ピリミジン化合物 |
| ES2685661T3 (es) * | 2013-11-08 | 2018-10-10 | Ono Pharmaceutical Co., Ltd. | Derivado de pirrolopirimidina |
| CA2929188C (en) | 2013-11-20 | 2022-08-09 | Signalchem Lifesciences Corp. | Quinazoline derivatives as tam family kinase inhibitors |
| US10233176B2 (en) | 2013-11-27 | 2019-03-19 | Signalchem Lifesciences Corporation | Aminopyridine derivatives as TAM family kinase inhibitors |
| CA2946538A1 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
| WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
| US20190099413A1 (en) | 2016-02-26 | 2019-04-04 | Ono Pharmaceutical Co., Ltd. | Drug for cancer therapy characterized in that axl inhibitor and immune checkpoint inhibitor are administered in combination |
| EP3436461B1 (en) | 2016-03-28 | 2023-11-01 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
| CN108250200A (zh) * | 2016-12-28 | 2018-07-06 | 中国科学院上海药物研究所 | 一种具有Axl抑制活性的化合物及其制备和应用 |
| EP3673907A4 (en) | 2017-08-23 | 2020-08-19 | ONO Pharmaceutical Co., Ltd. | CANCER TREATMENT PHARMACEUTICAL INCLUDING AX1 INHIBITOR AS AN EFFECTIVE INGREDIENT |
| MY208007A (en) | 2017-09-27 | 2025-04-04 | Incyte Corp | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
| JP7223998B2 (ja) | 2017-10-13 | 2023-02-17 | 小野薬品工業株式会社 | Ａｘｌ阻害剤を有効成分として含む固形がん治療剤 |
| CN112243374A (zh) * | 2018-01-29 | 2021-01-19 | 卡普勒斯疗法有限责任公司 | 包括6元中心环的srebp抑制剂 |
| CN112074505B (zh) | 2018-03-08 | 2024-04-05 | 因赛特公司 | 作为PI3K-γ抑制剂的氨基吡嗪二醇化合物 |
| AR117600A1 (es) | 2018-06-29 | 2021-08-18 | Incyte Corp | Formulaciones de un inhibidor de axl / mer |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| TWI840378B (zh) * | 2018-07-04 | 2024-05-01 | 日商第一三共股份有限公司 | 二芳基吡啶衍生物之製造方法 |
| WO2020038460A1 (zh) * | 2018-08-24 | 2020-02-27 | 南京药捷安康生物科技有限公司 | 一种新型的喹啉衍生物抑制剂 |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| US11718612B2 (en) | 2019-09-06 | 2023-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
| CN112625026B (zh) * | 2019-09-24 | 2022-09-09 | 药捷安康(南京)科技股份有限公司 | Tam家族激酶抑制剂的喹啉衍生物 |
| IL291665B2 (en) | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021108198A1 (en) * | 2019-11-26 | 2021-06-03 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4114401A1 (en) | 2020-03-06 | 2023-01-11 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| JPWO2022220227A1 (enExample) * | 2021-04-14 | 2022-10-20 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL205322B1 (pl) * | 1999-05-07 | 2010-04-30 | Encysive Pharmaceuticals Inc | Pochodne kwasu propionowego, środek farmaceutyczny i zastosowanie pochodnych kwasu propionowego |
| EP1136485A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | Aminophenyl pyrimidone derivatives |
| IL163547A0 (en) | 2002-02-12 | 2005-12-18 | Quark Biotech Inc | Use of the axl receptor for diagnosis and treatment of renal disease |
| WO2007030680A2 (en) | 2005-09-07 | 2007-03-15 | Rigel Pharmaceuticals, Inc. | Triazole derivatives useful as axl inhibitors |
| WO2007057399A2 (en) | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer with indole derivatives |
| BRPI0619424B1 (pt) | 2005-12-05 | 2022-02-08 | Pfizer Products Inc | Uso de inibidores c-met/hgfrs para a fabricação de medicamentos |
| JP5400388B2 (ja) | 2005-12-15 | 2014-01-29 | ライジェル ファーマシューティカルズ， インコーポレイテッド | キナーゼインヒビターおよびその利用 |
| EP1900727A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
| WO2008045978A1 (en) | 2006-10-10 | 2008-04-17 | Rigel Pharmaceuticals, Inc. | Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors |
| GB0625659D0 (en) | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US8012965B2 (en) | 2006-12-29 | 2011-09-06 | Rigel Pharmaceuticals, Inc. | Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| ME01832B (me) | 2006-12-29 | 2014-12-20 | Rigel Pharmaceuticals Inc | Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori |
| EP2114954B1 (en) | 2006-12-29 | 2013-02-13 | Rigel Pharmaceuticals, Inc. | Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors |
| US9650391B2 (en) | 2006-12-29 | 2017-05-16 | Rigel Pharmaceuticals Inc. | N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors |
| ES2656496T3 (es) | 2006-12-29 | 2018-02-27 | Rigel Pharmaceuticals, Inc. | Triazoles sustituidos útiles como inhibidores de AXL |
| CA2682733A1 (en) | 2007-04-13 | 2008-10-23 | Supergen, Inc. | Axl kinase inhibitors |
| GB0713259D0 (en) | 2007-07-09 | 2007-08-15 | Astrazeneca Ab | Pyrazine derivatives 954 |
| JP2010533159A (ja) * | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物９４７ |
| WO2009024825A1 (en) | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| RU2010120536A (ru) * | 2007-10-25 | 2011-11-27 | Астразенека Аб (Se) | Производные пиридина и пиразина, полезные для лечения клеточных проферативных расстройств |
| MX2010004491A (es) * | 2007-10-25 | 2010-06-21 | Astrazeneca Ab | Derivados de piridina y pirazina utiles en el tratamiento de trastornos proliferativos celulares. |
| EP2205592B1 (en) * | 2007-10-26 | 2013-05-08 | Rigel Pharmaceuticals, Inc. | Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| JP2011502991A (ja) | 2007-11-02 | 2011-01-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 骨癌並びに骨癌に伴う骨喪失及び骨痛の処置又は予防のためのｃｆｍｓ阻害物質の使用 |
| KR101596527B1 (ko) | 2008-01-23 | 2016-02-22 | 브리스톨-마이어스 스큅 컴퍼니 | ４-피리디논 화합물 및 암에 대한 그의 용도 |
| JP5693239B2 (ja) | 2008-01-23 | 2015-04-01 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ４−ピリジノン化合物および癌についてのその使用 |
| KR101325237B1 (ko) | 2008-04-16 | 2013-11-04 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ａｘｌ 키나아제 억제제인 퀴놀린 유도체 |
| UY31800A (es) | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| WO2009138799A1 (en) | 2008-05-14 | 2009-11-19 | Astex Therapeutics Limited | Therapeutic uses of 1-cycl0pr0pyl-3 - [3- ( 5 -morpholin- 4 -ylmethyl- 1h-benz0imidaz0l- 2 -yl) -lh-pyrazol-4-yl] -urea |
| JP5592884B2 (ja) | 2008-07-09 | 2014-09-17 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｘｌ阻害剤として有用な多環式ヘテロアリール置換トリアゾール |
| SI2328888T1 (sl) | 2008-07-09 | 2013-03-29 | Rigel Pharmaceuticals, Inc. | Premoščeni biciklični heteroaril substituirani triazoli, uporabni kot inhibitorji Axl |
| SG172857A1 (en) | 2009-02-09 | 2011-08-29 | Supergen Inc | Pyrrolopyrimidinyl axl kinase inhibitors |
| BRPI1015259A2 (pt) * | 2009-04-27 | 2016-05-03 | Elan Pharm Inc | antagonistas de piridinona de integrinas alfa-4 |
| EP2311809A1 (en) | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
| JP5970003B2 (ja) | 2011-03-04 | 2016-08-17 | ローカス ファーマシューティカルズ インコーポレイテッド | アミノピラジン化合物 |
-
2013
- 2013-01-30 NZ NZ627586A patent/NZ627586A/en not_active IP Right Cessation
- 2013-01-30 BR BR112014018702-9A patent/BR112014018702B1/pt not_active IP Right Cessation
- 2013-01-30 ES ES13743985.7T patent/ES2617484T3/es active Active
- 2013-01-30 HR HRP20170303TT patent/HRP20170303T1/hr unknown
- 2013-01-30 SG SG11201404505PA patent/SG11201404505PA/en unknown
- 2013-01-30 PL PL13743985T patent/PL2810937T3/pl unknown
- 2013-01-30 US US13/753,926 patent/US8933103B2/en active Active
- 2013-01-30 CN CN201380017353.6A patent/CN104185627B/zh active Active
- 2013-01-30 LT LTEP13743985.7T patent/LT2810937T/lt unknown
- 2013-01-30 JP JP2013556479A patent/JP6006241B2/ja not_active Expired - Fee Related
- 2013-01-30 HU HUE13743985A patent/HUE031624T2/en unknown
- 2013-01-30 WO PCT/JP2013/052111 patent/WO2013115280A1/ja not_active Ceased
- 2013-01-30 SI SI201330421A patent/SI2810937T1/sl unknown
- 2013-01-30 SM SM20170065T patent/SMT201700065T1/it unknown
- 2013-01-30 AU AU2013216006A patent/AU2013216006B2/en not_active Ceased
- 2013-01-30 EP EP13743985.7A patent/EP2810937B1/en active Active
- 2013-01-30 MY MYPI2014002198A patent/MY165215A/en unknown
- 2013-01-30 CA CA2863515A patent/CA2863515C/en active Active
- 2013-01-30 PT PT137439857T patent/PT2810937T/pt unknown
- 2013-01-30 MX MX2014009246A patent/MX351812B/es active IP Right Grant
- 2013-01-30 DK DK13743985.7T patent/DK2810937T3/en active
- 2013-01-30 TW TW102103411A patent/TWI537259B/zh active
- 2013-01-30 RU RU2014135401A patent/RU2632885C2/ru active
- 2013-01-30 KR KR1020147020852A patent/KR102078530B1/ko not_active Expired - Fee Related
- 2013-01-30 RS RS20170211A patent/RS55728B1/sr unknown
-
2014
- 2014-07-24 ZA ZA2014/05486A patent/ZA201405486B/en unknown
- 2014-07-30 PH PH12014501719A patent/PH12014501719B1/en unknown
- 2014-07-30 IL IL233863A patent/IL233863A/en active IP Right Grant
- 2014-08-28 CO CO14189810A patent/CO7071126A2/es unknown
-
2017
- 2017-01-30 SM SM201700065T patent/SMT201700065B/it unknown
- 2017-02-23 CY CY20171100251T patent/CY1118656T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI537259B (zh) | 吡啶酮衍生物 | |
| JP6507216B2 (ja) | ２−（モルホリン−４−イル）−１，７−ナフチリジン | |
| TWI606039B (zh) | Ａｐｊ受體之三唑激動劑 | |
| KR102181915B1 (ko) | Trka 키나아제 억제제로서 n-피롤리디닐, n'-피라졸릴-우레아, 티오우레아, 구아니딘 및 시아노구아니딘 화합물 | |
| WO2013162061A1 (ja) | 二環性ピリミジン化合物 | |
| CA3142069A1 (en) | Aurora kinase inhibitor and use thereof | |
| CN115141215A (zh) | Kras g12d蛋白抑制剂和其用途 | |
| JP2017101055A (ja) | テトラヒドロピラニルメチル基を有するピリドン誘導体 | |
| TW201718534A (zh) | ３－胺基－１，５，６，７－四氫－４ｈ－吲哚－４－酮 | |
| JP2023525116A (ja) | 免疫調節剤としてのビアリール環結合芳香族複素環誘導体の調製およびその適用 | |
| US10160745B2 (en) | Piperidine and azepine derivatives as prokineticin receptor modulators | |
| CN116134022A (zh) | Atr抑制剂和其用途 | |
| KR102160841B1 (ko) | 2-피리돈 화합물 | |
| RU2615986C1 (ru) | Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения | |
| HK1203504B (en) | Pyridone derivative | |
| CN121013856A (zh) | Egfr降解剂、其药物组合物及其用途 | |
| CN119013017A (zh) | 包含抗癌剂和对前列腺素e2受体具有抑制活性的新化合物的用于治疗癌症的药物组合物 | |
| EA047234B1 (ru) | Иммуномодуляторы, композиции и способы с их использованием | |
| HK1233633A1 (en) | Derivatives of macrocyclic n-aryl-2-amino-4-aryl-pyrimidine polyethers as inhibitors of ftl3 and jak |